Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
AGTC is a clinical-stage biotechnology company that uses a proprietary gene therap...
AGTC is a clinical-stage biotechnology company ...
Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an innovative biopharmaceutical company ...
Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an in...
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicat...
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI...
At PRA Health Sciences, we work side-by-side with our clients, to move drug discov...
At PRA Health Sciences, we work side-by-side wi...
Edesa Biotech Inc. is a clinical-stage biopharmaceutical company founded by expert...
Edesa Biotech Inc. is a clinical-stage biopharm...
We have used biochemical, molecular & cell biology and in vivo models to screen, i...
We have used biochemical, molecular & cell biol...
Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery...
Spring Bank is a clinical-stage biopharmaceutic...
Join the National Investor Network and get the latest information with your interests in mind.